Emerald Mutual Fund Advisers Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-107	Closed	-$112K	–	233
2024 Q3	$112K	Hold	107	–	–	0.01%	216
2024 Q2	$112K	Sell	107 -50	-32%	-$48.5K	0.01%	210
2024 Q1	$151K	Sell	157 -5	-3%	-$4.75K	0.01%	203
2023 Q4	$142K	Buy	162 +22	+16%	+$18.1K	0.01%	227
2023 Q3	$115K	Buy	140 +52	+59%	+$40.9K	0.01%	217
2023 Q2	$63.2K	Buy	+88	New	+$67.8K	﹤0.01%	237
2020 Q4	–	Sell	-153	Closed	-$86K	–	314
2020 Q3	$86K	Buy	+153	New	+$92.8K	﹤0.01%	262

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's REGN Position: Q4 2024 in Review

Emerald Mutual Fund Advisers Trust sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 107 shares — an estimated $112K sold.

Emerald Mutual Fund Advisers Trust first reported a position in REGN in Q3 2020 and held it in 7 quarters. The position peaked at $151K in Q1 2024. 1,320 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Emerald Mutual Fund Advisers Trust reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 107 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $112K.
Emerald Mutual Fund Advisers Trust first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 7 quarters.
Emerald Mutual Fund Advisers Trust's Regeneron Pharmaceuticals position peaked at $151K in Q1 2024.
1,320 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2024, filed 14 Feb 2025.